STAT6 pathway activation is associated with poor prognosis in multiple cancers including hepatocellular carcinomas (HCC) and patients with high STAT6 activation may potentially benefit from exoASO ...

KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human ...

STAT6 pathway activation is associated with poor prognosis in multiple cancers including hepatocellular carcinomas (HCC) and patients with high STAT6 activation may potentially benefit from exoASO ...

About STAT6 Degrader STAT6 is a historically undrugged essential transcription factor in the IL-4/IL-13 signaling pathways and the central driver of T helper type 2 (TH2) inflammation in allergic ...

Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation Nurix anticipates ...

"By partnering with LEO Pharma, we hope to explore the potential of the STAT6 pathway to bring forward an oral option for patients suffering from chronic inflammatory conditions," said Flavius ...

Key takeaways: The STAT5 and STAT6 transcription factors activate Th9 cells. Th9 cells produce the IL-9 cytokine, which causes allergic inflammation. Th9 levels may indicate which patients may ...

In allergic diseases, STAT6 is a critical transcription factor in the IL-4 and IL-13 signaling pathways and the key driver of Th2 inflammation. Because STAT6 functions through protein-protein and ...

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from ...